Norman Fields Gottscho Capital Management LLC Buys 19,870 Shares of Novo Nordisk A/S (NYSE:NVO)

Norman Fields Gottscho Capital Management LLC raised its stake in Novo Nordisk A/S (NYSE:NVO) by 45.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 63,732 shares of the company’s stock after buying an additional 19,870 shares during the period. Novo Nordisk A/S comprises about 1.8% of Norman Fields Gottscho Capital Management LLC’s portfolio, making the stock its 15th biggest position. Norman Fields Gottscho Capital Management LLC’s holdings in Novo Nordisk A/S were worth $5,482,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in NVO. International Assets Investment Management LLC lifted its holdings in Novo Nordisk A/S by 10,608.4% in the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after buying an additional 1,796,635 shares during the period. DSM Capital Partners LLC lifted its stake in shares of Novo Nordisk A/S by 257,816.0% in the 2nd quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock valued at $227,516,000 after purchasing an additional 1,593,303 shares during the period. Mediolanum International Funds Ltd bought a new stake in shares of Novo Nordisk A/S during the 3rd quarter valued at about $98,765,000. Marshall Wace LLP grew its stake in Novo Nordisk A/S by 34,472.1% during the second quarter. Marshall Wace LLP now owns 691,441 shares of the company’s stock worth $98,696,000 after purchasing an additional 689,441 shares during the period. Finally, Wellington Management Group LLP bought a new stake in Novo Nordisk A/S in the third quarter worth approximately $42,017,000. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Trading Down 3.1 %

NVO opened at $84.95 on Tuesday. The firm has a market capitalization of $381.22 billion, a PE ratio of 27.49, a P/E/G ratio of 1.37 and a beta of 0.45. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. Novo Nordisk A/S has a fifty-two week low of $81.50 and a fifty-two week high of $148.15. The company’s 50-day moving average is $102.51 and its 200 day moving average is $120.68.

Analysts Set New Price Targets

A number of equities analysts have issued reports on NVO shares. BMO Capital Markets cut their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Moderate Buy” and a consensus price target of $140.20.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.